Piper Sandler lowered the firm’s price target on Omnicell (OMCL) to $49 from $63 and keeps an Overweight rating on the shares. The firm notes the company reported mixed Q4 results and issued muted 2026 guidance against high expectations and positive sentiment. Management is excited about the Titan XT launch, but warned that much of the $2.5B replacement opportunity needs to mature before it can convert.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL:
- Omnicell: Solid Execution and Strategic Promise Offset by Near-Term Profitability Pressures and Premium Valuation (Hold Rating Maintained)
- Omnicell reports Q4 adjusted EPS 40c, consensus 50c
- Omnicell sees Q1 adjusted EPS 26c-36c, consensus 27c
- Omnicell sees FY26 adjusted EPS $1.65-$1.85, consensus $1.88
- Omnicell management to meet with Piper Sandler